BioZapetite delivers orforglipron (6 mg), a first-in-class oral, small-molecule GLP-1 receptor agonist designed for investigational use. Unlike peptide GLP-1 agonists, orforglipron is orally bioavailable without fasting or water restrictions and demonstrates robust pharmacology in glucose and weight regulation.
Together, its mechanisms are designed to:
- Promote glucose disposal & insulin sensitivity by enhancing glucose-dependent insulin secretion, suppressing glucagon, and improving post-prandial glucose control [1][3].
- Drive weight reduction & appetite control through central satiety signaling, slowed gastric emptying, and consistent reductions in caloric intake [1][2].
- Improve lipid & cardiometabolic health via secondary benefits of weight loss, including reductions in blood pressure, triglycerides, and waist circumference [1][3].
- Provide oral dosing convenience with a ~29–49 h half-life supporting once-daily use and no need for co-formulated absorption enhancers [4][6].
- Exhibit a safety profile consistent with injectable GLP-1 medicines, dominated by mild-to-moderate GI events during dose titration, with no hepatic safety signal in Phase 3 readouts [3][5].
These complementary mechanisms make BioZapetite a promising candidate for research in weight regulation, glycemic control, and cardiometabolic health.
BioZapetite Structure
| Ingredient | Dose (per capsule) | Key Actions |
| Orforglipron | 6 mg | Non-peptide GLP-1R agonist; enhances insulin secretion, ↓glucagon, ↓appetite, slows gastric emptying; t½ ~29–49 h; oral bioavailability without fasting/water restrictions [1][3][4][6] |
Research Areas
- Appetite Regulation & Body Weight
- Glucose Disposal & Glycemic Control
- Cardiometabolic Risk Reduction
- Oral Small-Molecule Incretin Pharmacology
Translational Safety & GI Tolerability
